



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimballa
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messenger
Judith U. Kim
Jeffrey T. Helvey

Eldora L. Ellison
Donald R. Banowitz
Peter A. Jackman
Brian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Edward W. Yee
Virgil Lee Beaton
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis

Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gabby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
Young Tang
Christopher J. Walsh

W. Blake Coblenz
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek
Carla Ji-Eun Kim
Doyle A. Siever
Alexandra K. Pechhold
C. Matthew Rozier
Robert A. Schwartzman
Bryan L. Skelton
Ulrike Winkler

Registered Patent Agents
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Julie A. Heider

Mita Mukherjee
Scott M. Woodhouse
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Asthana

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

March 6, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8637

INTERNET ADDRESS:
KAREN@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1643

Attn: Mail Stop AF

Re: U.S. Utility Patent Application
Application No. 09/720,086; § 371 Date: July 23, 2001
For: **De Novo DNA Cytosine Methyltransferase
Genes, Polypeptides and Uses Thereof**
Inventors: *LI et al.*
Our Ref: 0609.4560002/KRM/DJN

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$1,520.00 to cover: \$1,020.00- Petition for Extension of Time fee for three months and \$500.00- Notice of Appeal fee;
2. Petition for Extension of Time Under 37 C.F.R. 1.136(a);
3. Notice of Appeal From the Examiner to the Board of Patent Appeals and Interferences - Large Entity;
4. Supplemental Amendment and Reply Under 37 C.F.R. 1.116;
5. Courtesy copy of Examiner Interview Summary dated 2/27/2007; and
6. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 6, 2007
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

KRM/DJN:dbj
Enclosures

648410_1.DOC



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/720,086	07/23/2001	En Li	0609.4560002	6968

26111 7590 02/27/2007
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20005

EXAMINER
HARRIS, ALANA M

ART UNIT PAPER NUMBER
1643


MAIL DATE DELIVERY MODE
02/27/2007 PAPER

DUPLICATE

Please find below and/or attached an Office communication concerning this application or proceeding.

MAR 1 2007

mo mm 3/2
KRM ILM 3/2
DSN ~~DSN~~

Interview Summary

Application No.

09/720,086

Applicant(s)

LI ET AL.

Examiner

Alana M. Harris, Ph.D.

Art Unit

1643

All participants (applicant, applicant's representative, PTO personnel):

(1) Alana M. Harris, Ph.D.(3) Dan Nevriy.(2) Karen R. Markowicz.

(4) _____.

Date of Interview: 04 December 2006.Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant2) ☐ applicant's representative]Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.Claim(s) discussed: 1,3-10,13 and 25-50.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☒ N/A.Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

ALANA M. HARRIS, PH.D.
PRIMARY EXAMINER12/04/2006Examiner Note: You must sign this form unless it is an
Attachment to a signed Office action.

Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Participants discussed specifically independent claims 1, 8-10, 31, 38 and 44. The Examiner made claim language suggestions to fellow participants, such as adding the recitation "fully" for sections f and e of claims that read on a single polynucleotide sequence. Participants also discussed the pending double patenting rejection, as well as 112, 1st written description rejection of claim 10. Participants pointed out page 11, lines 4-7 and page 21, lines 7-25 as support for claim 10. The Examiner noted to fellow participants that she would review those passages of the specification and reconsider all pending issues upon receipt of after-final response..